Genmab ASFRA:GE91 -2.42%94 PB Ratio is 3.02 as of Jul. 08, 2026, which is 60% below its 10-year median of 7.49. GuruFocus rates FRA:GE91 with a GF Score™ of 94/100 and a GF Value™ of €29.34 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,225 Biotechnology companies, Genmab AS ranks worse than 53.31% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-08), Genmab AS's share price is €24.20. Genmab AS's Book Value per Share for the quarter that ended in Mar. 2026 was €8.01. Hence, Genmab AS's PB Ratio of today is 3.02.
The historical rank and industry rank for Genmab AS's PB Ratio or its related term are showing as below:
FRA:GE91'
s PB Ratio Range Over the Past 10 Years
Min: 2.12 Med: 7.49 Max: 19.72
Current: 3.17
During the past 13 years, Genmab AS's highest PB Ratio was 19.72. The lowest was 2.12. And the median was 7.49.
FRA:GE91's PB Ratio is ranked worse than 53.31% of 1225
companies
in the Biotechnology industry
Industry Median: 2.92
vs FRA:GE91: 3.17
During the past 12 months, Genmab AS's average Book Value Per Share Growth Rate was 3.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 12.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 16.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 27.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Genmab AS was 97.10% per year. The lowest was -40.50% per year. And the median was 18.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Genmab AS PB Ratio Related Terms
Genmab AS PB Ratio Historical Data
* Premium members only.
The historical data trend for Genmab AS's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Genmab AS's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genmab AS PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genmab AS's PB Ratio distribution charts can be found below:
* The bar in red indicates where Genmab AS's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Genmab AS's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Genmab AS (FRA:GE91) has a PB Ratio of 3.02 as of Jul. 08, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Genmab AS and its competitors. This is 60% below median its historical median of 7.49. Over the past decade, Genmab AS's PB Ratio has ranged from 2.12 to 19.72. According to the industry distribution chart, Genmab AS ranks #653 out of 1225 companies in the Biotechnology industry, placing it in the top 53.3%.
Is Genmab AS's PB Ratio too high?
Genmab AS's current PB Ratio of 3.02 is 60% below median its 10-year median of 7.49. Over the past 10 years, this metric has ranged from a low of 2.12 to a high of 19.72. The Biotechnology industry median PB Ratio is 2.92. Genmab AS's value of 3.02 is 3.4% above this industry median. Based on the distribution chart, Genmab AS ranks #653 out of 1225 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Genmab AS has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genmab AS ranks #653 out of 1225 companies for PB Ratio. This places Genmab AS in the lower half of its industry. The industry median PB Ratio is 2.92. Genmab AS's value of 3.02 is 3.4% above this benchmark. Historically, Genmab AS's own PB Ratio has ranged from 2.12 to 19.72 over the past decade. While the company's 10-year median is 7.49 vs. the industry median of 2.92, Genmab AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.92, based on 1,225 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genmab AS's current PB Ratio of 3.02 is 3.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Genmab AS and its competitors. For the Biotechnology industry, the median PB Ratio is 2.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genmab AS's current PB Ratio is 3.02, which is 60% below median its own 10-year median of 7.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (FRA:GE91) is currently considered Modestly Undervalued. The stock's GF Value™ is €29.34, compared to a current price of €24.20 — trading 17.5% below its estimated fair value. The current PB Ratio is 3.02, which is 60% below median its 10-year median of 7.49 and 3.4% above the Biotechnology industry median of 2.92. Genmab AS's overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Genmab AS (FRA:GE91), the current PB Ratio is 3.02 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genmab AS (FRA:GE91) Overvalued in 2026?
Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued.
The current stock price of €24.20 is trading 17.5% below its estimated GF Value™ of €29.34.
GuruFocus considers Genmab AS to be Modestly Undervalued.
Key valuation signals for FRA:GE91:
PB Ratio: 3.02 (60% below median its 10-year median of 7.49)
GF Value™: €29.34 vs. price of €24.20 (17.5% below fair value)
Industry Position: 3.4% above the Biotechnology median (#653 of 1225)
No single metric tells the full story. See the FRA:GE91 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
94GF Score
Get the complete analysis for FRA:GE91
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GE91 has been successfully added to your 
